Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
- Conditions
- Myelodysplastic SyndromesHematopoietic Cell Transplant
- Interventions
- Behavioral: ePRO survey
- First Posted Date
- 2018-06-15
- Last Posted Date
- 2020-12-02
- Target Recruit Count
- 92
- Registration Number
- NCT03558386
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population
- Conditions
- iPS Cell Manufacture and Banking
- First Posted Date
- 2018-02-15
- Last Posted Date
- 2020-07-15
- Target Recruit Count
- 19
- Registration Number
- NCT03434808
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Other: Allogeneic Hematopoietic Stem Cell Transplant
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2023-08-30
- Target Recruit Count
- 544
- Registration Number
- NCT03127761
- Locations
- 🇺🇸
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota, United States
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- Conditions
- Myelofibrosis
- Interventions
- Other: Hematopoietic Stem Cell Transplant
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2023-08-30
- Target Recruit Count
- 650
- Registration Number
- NCT02934477
- Locations
- 🇺🇸
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota, United States
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
- Conditions
- Myelodysplastic Syndrome (MDS)Chronic Lymphocytic Leukemia (CLL)Chemotherapy-sensitive LymphomaAcute Lymphoblastic Leukemia (ALL)/T Lymphoblastic LymphomaAcute Myelogenous Leukemia (AML)Acute Biphenotypic Leukemia (ABL)Acute Undifferentiated Leukemia (AUL)
- Interventions
- Radiation: Total Body Irradiation (TBI) 200cGy on Day -1Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1Procedure: Infusion of non-T-cell depleted bone marrow on Day 0
- First Posted Date
- 2016-06-08
- Last Posted Date
- 2020-12-02
- Target Recruit Count
- 80
- Registration Number
- NCT02793544
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center - Adults, New York, New York, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program, Richmond, Virginia, United States
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Biological: Moxetumomab Pasudotox
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2015-09-16
- Target Recruit Count
- 1
- Registration Number
- NCT02338050
- Locations
- 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies
- Conditions
- Juvenile Myelomonocytic LeukemiaChronic Myelogenous LeukemiaAcute Myelogenous LeukemiaAcute Lymphoblastic Leukemia/LymphomaMyelodysplasia
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2023-02-08
- Target Recruit Count
- 340
- Registration Number
- NCT02338479
- Locations
- 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Dana Farber Cancer Institute - Pediatrics, Boston, Massachusetts, United States
Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors
- Conditions
- Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT
- Interventions
- Other: Individualized Survivorship Care Plan (SCP)
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2017-09-07
- Target Recruit Count
- 495
- Registration Number
- NCT02200133
- Locations
- 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
- Conditions
- Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-10-12
- Target Recruit Count
- 40
- Registration Number
- NCT01772953
- Locations
- 🇺🇸
Washington University, St. Louis Children's, St. Louis, Missouri, United States
🇺🇸Children's National Medical Center, Washington, DC, District of Columbia, United States
🇺🇸Children's Hospital of Alabama/UAB, Birmingham, Alabama, United States
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
- Conditions
- Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family MemberMyelodysplastic SyndromeHodgkin's DiseaseChronic Lymphocytic LeukemiaAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous LeukemiaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2012-10-01
- Last Posted Date
- 2023-09-14
- Target Recruit Count
- 127
- Registration Number
- NCT01696461
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Ohio State University, Columbus, Ohio, United States